Altria's Q2 and H1 Results: Net Revenue Falls 4.6% to $6.209 Billion in Q2 Amid Notable Market Share Growth for NJOY

Business by 2FIRSTS.ai
Aug.01.2024
Altria's Q2 and H1 Results: Net Revenue Falls 4.6% to $6.209 Billion in Q2 Amid Notable Market Share Growth for NJOY
Altria Group's Q2 earnings report shows 4.6% decrease in net income, driven by declining revenue from smoking products.

On July 31, Altria Group, Inc. released its performance report for the second quarter and first half of 2024 on its official website. According to the report, net income for the second quarter was $6.209 billion, a decrease of 4.6% year-on-year, with revenue after excise tax decreasing by 3% to $5.28 billion. For the first half of the year, net income decreased by 3.6% to $11.8 billion, with revenue after excise tax decreasing by 2.0% to $10 billion. The main reason for the decline in revenue was a decrease in income from the combustible products division, although an increase in revenue from oral tobacco products partially offset this impact.

 

Altria's Q2 and H1 Results: Net Revenue Falls 4.6% to $6.209 Billion in Q2 Amid Notable Market Share Growth for NJOY

 

Due to financial constraints, consumers are turning to cheaper alternatives or e-cigarettes, putting pressure on demand for expensive brands. The company's total cigarette shipments in the second quarter dropped by 13%.

 

In the second quarter, NJOY's consumables shipment volume increased by 14.7% month-on-month to 12.5 million units, while equipment shipment volume increased by 80.0% to 1.8 million units. The product's retail share in the US multi-channel and convenience store channels increased by 1.3% month-on-month to 5.5%. In the first half of the year, NJOY's consumables shipment volume was 23.4 million units and equipment shipment volume was 2.8 million units, with the product's retail share in the US multi-channel and convenience store channels at 4.8%.

 

In June 2024, NJOY's four menthol-flavored e-cigarette products were granted market authorization by the FDA, including NJOY ACE Pod Menthol 2.4% and 5%, NJOY DAILY Menthol 4.5%, and NJOY DAILY Extra Menthol 6%. NJOY is the first and only company to receive FDA authorization for menthol-flavored e-cigarette products.

 

In addition, in the second quarter of the year, net revenue from oral tobacco products increased by 4.6%, with a 4.1% increase in net revenue for the first half of the year.

 

In the second quarter of this year, the market share of on! nicotine pouches in the oral tobacco products category in the United States was 8.1%, an increase of 1.2% from last year and a 1% increase from the previous quarter. The product's market share in the nicotine pouch category was 19.4%, a decrease of 4.2% compared to last year but an increase of 1.8% from the previous quarter. In the first half of the year, on! nicotine pouches held a total market share of 7.6% in the oral tobacco products category in the United States, an increase of 0.9% from last year. The nicotine pouch category accounted for 40.9% of the oral tobacco products category in the United States, an increase of 12.9% from last year, while the product's market share in the nicotine pouch category decreased by 5.4% compared to last year.

 

Here are the key points distilled from the report:

 

  • In the first half of 2024, the adjusted diluted EPS decreased by 1.6%, in line with the company's weighted expectations for growth in the second half of the year; 
  • The full-year forecast for adjusted diluted EPS in 2024 narrowed to a range of $5.07 to $5.15, expecting a year-over-year increase of 2.5% to 4.0%, based on the 2023 figure of $4.95; 
  • The company's adjusted earnings per share were $1.31, lower than the expected $1.35; 
  • Through stock buybacks and dividends, the company returned over $5.8 billion in value to shareholders in the first half of 2024.

 

CEO of Aochiya, Billy Gifford, stated that,

 

As we pursue the vision of guiding adult smokers responsibly towards a smoke-free future, the momentum of Achiea continues to strengthen.

 

In the second quarter, our company's innovative smoke-free products achieved strong market share and sales performance. We also reached significant milestones that we believe lay the foundation for future success. NJOY received FDA approval for the first and only menthol-flavored e-cigarette product on the market, and we submitted PMTA applications for NJOY ACE 2.0 and on! PLUS to the FDA.

 

Despite facing challenging operating conditions, our traditional tobacco business has remained resilient. Our high cash generating business has supported our continued investments in innovative products, and in the first half of this year, we returned over $5.8 billion in value to shareholders through stock buybacks and dividends.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Japan Tobacco (JT) launched a refreshed Ploom CUBE design in Japan on September 8, 2026, with broader convenience-store and tobacco-retail distribution planned from October 13. The updated device retains the existing Rounded Cube form and heating platform while replacing four previous body colors with Pebble White and Cobalt Black. JT is also introducing new Front Panels and Fabric Back Covers, although the new accessories are not compatible with the previous Ploom CUBE design. The company says the update is intended to broaden appeal among younger male and female users.
Sep.09
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
The HQD SiSA 80K Hookah Disposable Vape has appeared across U.S. and cross-border online retail channels. The device comes prefilled with 28ml of e-liquid, uses a 5% nicotine salt configuration and carries a brand claim of up to 80,000 puffs. Beyond puff count, the product differentiates itself through hookah-inspired features including adjustable airflow, a flowing-water sound effect and flavor options associated with traditional hookah consumption.
Aug.18
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
BAT Rothmans says it previously considered exiting South Korea's vaping market because of competitive pressure from unregulated products, but is now reassessing conditions following changes to the country's nicotine regulatory framework. Vuse and other BAT vaping products remain available through existing distribution channels. The statement followed a South Korean media report that interpreted BAT's broader withdrawal from selected Vapour markets as a full exit from South Korea. Meanwhile, Philip Morris International launched VEEV inPRIME in the country in June and began expanding distribution to around 14,000 convenience stores and other retail channels in July. The contrasting moves highlight differing investment strategies as South Korea's regulated vaping market evolves.
Aug.14
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04